Literature DB >> 9403226

Motor complications of chronic levodopa therapy in Parkinson's disease.

E Miyawaki1, K Lyons, R Pahwa, A I Tröster, J Hubble, D Smith, K Busenbark, D McGuire, D Michalek, W C Koller.   

Abstract

We report on motor complications of chronic levodopa therapy among 811 levodopa-responsive patients with idiopathic Parkinson's disease (PD), stratified by duration after diagnosis. Predictable "offs" were noted in 20.2% of patients in the first 5 years, in 58.3% after 15 years. Unpredictable or sudden offs and early morning dystonia were less common. Longer duration was associated with greater percentages of patients with off periods or dyskinesias (up to 70% after 15 years), although patients with 6-15 years' duration saw relatively little increase in frequency of those complications, and a minority of patients (approximately 30%) with duration into the second decade did not experience off periods or dyskinesia. Across groups, mean Hoehn and Yahr stage and daily levodopa dosage progressively increase (and mean Schwab and England disability ratings decrease), but more conservatively than in prior reports in the postlevodopa era. We note that with advancing PD duration, levodopa complications are more common, but in many cases there appear to be relatively stable periods in terms of levodopa dosage and disease severity, and a minority of patients will be relatively free of motor complications into the second decade of their disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403226     DOI: 10.1097/00002826-199712000-00004

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

Review 1.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

Review 2.  When should levodopa therapy be initiated in patients with Parkinson's disease?

Authors:  Irene A C Halkias; Ihtsham Haq; Zhigao Huang; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

4.  The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features.

Authors:  Alessandra Nicoletti; Pierfrancesco Pugliese; Giuseppe Nicoletti; Gennarina Arabia; Grazia Annesi; Michele De Mari; Paolo Lamberti; Simone Gallerini; Roberto Marconi; Antonio Epifanio; Letterio Morgante; Autilia Cozzolino; Paolo Barone; Giuseppina Torchia; Aldo Quattrone; Mario Zappia
Journal:  Neurol Sci       Date:  2010-02       Impact factor: 3.307

5.  Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study.

Authors:  Wan Fung Kum; Siva Sundara Kumar Durairajan; Zhao Xiang Bian; Sui Cheung Man; Yuen Chi Lam; Li Xia Xie; Jia Hong Lu; Yan Wang; Xian Zhang Huang; Min Li
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-18       Impact factor: 2.629

6.  L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.

Authors:  Fabrizio Stocchi; Laura Vacca; Paola Grassini; Stephen Pawsey; Holly Whale; Stefano Marconi; Margherita Torti
Journal:  Parkinsons Dis       Date:  2015-06-10

7.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.